Comparative Pharmacology
Head-to-head clinical analysis: CHLORPHENIRAMINE MALEATE versus LIVOSTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPHENIRAMINE MALEATE versus LIVOSTIN.
CHLORPHENIRAMINE MALEATE vs LIVOSTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1 receptor antagonist; competitively blocks histamine at H1 receptors, preventing histamine-mediated symptoms such as vasodilation, increased capillary permeability, and smooth muscle contraction.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
4 mg orally every 4-6 hours, not to exceed 24 mg per day; or 10-20 mg intramuscularly or intravenously as a single dose, not to exceed 40 mg per day.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged in hepatic impairment).
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateTerminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Renal: ~50% as metabolites; Fecal: negligible; Biliary: minor.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Category C
Category C
Antihistamine
Antihistamine
Dexchlorpheniramine maleate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate."